The Glucagon Paradox in Next-Generation Incretin Therapy: How GLP-1, GIP, and Glucagon Receptor Co-Agonism May Amplify Weight Loss Despite Glucagon’s Hyperglycemic Biology D. Mcauley Abstract The development of dual and triple incretin-based receptor agonists represents a major advance in the pharmacologic treatment of obesity, type
Tag: incretin therapy
Ozempic Nation: Paradigm Shift or Public Health Mirage?
Ozempic Nation Paradigm Shift or Public Health Mirage Review Abstract The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies has transformed the management of obesity and type 2 diabetes mellitus. Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, initiated a major shift in
